Anavex Life Sciences Corp.
AVXL · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $38 | $42 | $44 | $38 |
| G&A Expenses | $14 | $11 | $12 | $13 |
| SG&A Expenses | $14 | $11 | $12 | $13 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $51 | $53 | $56 | $51 |
| Operating Income | $0 | -$53 | -$56 | -$51 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $10 | $8 | $3 |
| Pre-Tax Income | $0 | -$43 | -$47 | -$48 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | -$43 | -$48 | -$48 |
| % Margin | – | – | – | – |
| EPS | -0.54 | -0.52 | -0.6 | -0.62 |
| % Growth | -3.8% | 13.3% | 3.2% | – |
| EPS Diluted | -0.54 | -0.52 | -0.6 | -0.62 |
| Weighted Avg Shares Out | 85 | 83 | 80 | 77 |
| Weighted Avg Shares Out Dil | 85 | 83 | 80 | 77 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $7 | $7 | $1 |
| Interest Expense | $0 | $0 | $1 | $1 |
| Depreciation & Amortization | $0 | $51 | -$3 | -$3 |
| EBITDA | $0 | $5 | -$56 | -$51 |
| % Margin | – | – | – | – |